Novo-Nordisk's Victoza Approved For Type-2 Diabetes In China (NVO).

Symbols: NVO
Posted in: News, Legal, Global
Share

Novo-Nordisk's Victoza Approved For Type-2 Diabetes In China (NVO). The Chinese State Food And Drug Administration has approved Novo-Nordisk's (NYSE: NVO) Victoza for Type-2 diabetes treatment.


 
 
< Previous
Walgreen Reports Q2 EPS of $0.80
Next >
Nevada Awards HP $176 Million Medicaid Contract
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust